Phase 2 clinical trial on volitinib in papillary renal cell carcinoma

At the Thirteenth International Kidney Cancer Symposium, Dr Toni Choueiri (Dana-Farber Cancer Institute and Harvard Medical School, MA) discusses the new AstraZeneca-sponsored Phase 2 clinical trial on the c-Met inhibitor, volitinib, in patients with papillary renal cell carcinoma (pRCC).02/21/2015
Source: Kidney Cancer Association - Category: Cancer & Oncology Source Type: news